Phesgo logo

Author: welw

August undefined, 2024

WebThank you for visiting our site. You are about to leave the site to one that is not affiliated to Roche Products (New Zealand) Ltd. Roche Products (New Zealand) does not endorse or control, the content of any linked websites and if you click OK, you agree that Roche has no responsibility or duty to you for anything that happens to you as a result.

Dosing & Administration PHESGO® (pertuzumab / trastuzumab ...

WebPolicy. Precertification of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) is required of all Aetna participating providers and members in applicable plan designs. For precertification of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo), call (866) 752-7021 (Commercial), (866) 503-0857 (Medicare), or fax (888) 267-3277. WebOct 13, 2024 · PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection is a sterile, preservative-free, clear to opalescent, and colorless to slightly brownish solution … chip cash isa

Phesgo European Medicines Agency

Web600 mg pertuzumab, 600 mg trastuzumab, 20,000 units hyaluronidase per 10 mL supplied in a single-dose, ready-to-use vial. Administer subcutaneously over approximately 5 minutes at a rate of no more than 2 mL/min. Observe for hypersensitivity or administration-related reactions: minimum of 15 minutes*. NDC: 50242-260-01. WebApr 14, 2024 · Phesgo contains less than 1 mmol sodium (23 mg) per dose, ie essentially ‘sodium-free’. How to get Phesgo. Phesgo will be given to you by a doctor or nurse at a hospital or clinic. Phesgo is given as an injection under the skin ( subcutaneous injection ). The injection will be given every three weeks. WebPhesgo® contains pertuzumab, trastuzumab, and hyaluronidase-zzxf. It is best to read this information with our general information about breast cancer. These treatments belong to a group of targeted therapy drugs known as monoclonal antibodies. They both work by targeting specific proteins (receptors). chip castille

HIGHLIGHTS OF PRESCRIBING INFORMATION The …

Phesgo: Package Insert / Prescribing Information

WebPHESGO ® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for: use prior to surgery (neoadjuvant treatment) in adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). WebWith the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $5 per treatment for PHESGO. Co-pay assistance of up to $25,000 is provided per calendar year. Are over the age of 18, or have a Legally Authorized Person over the age of 18 to manage the program. chip casteenWebJun 29, 2024 · SAN DIEGO, June 29, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved Roche's Phesgo™ (pertuzumab,... chip carving images

"WebJun 29, 2024 · The safety profile of PHESGO is comparable to intravenous pertuzumab and trastuzumab, except for increased administration-related reactions. The most common adverse reactions in >30% patients... " - Phesgo logo

Phesgo logo

Dosing & Administration PHESGO® (pertuzumab / …

WebMar 25, 2024 · This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer … WebJan 1, 2024 · Phesgo 600 mg/600 mg/20,000 units (providing 600 mg pertuzumab, 600 mg trastuzumab and 20,000 units hyaluronidase per 10 mL) single-dose vials: 50242-0260-xx VII. References 1. Phesgo [package insert]. South San Francisco, CA; Genentech, Inc; June 2024. Accessed August 2024. 2.

Did you know?

WebAug 8, 2024 · Phesgo is a cancer medicine that is used alone or with other medicines to treat early-stage breast cancer. Phesgo is also used to treat HER2-positive breast cancer that is advanced or has spread to other parts of the body (metastatic). Phesgo is used for breast cancer only if your tumor tests positive for a protein called human epidermal … WebPhesgo® contains two separate monoclonal antibodies, trastuzumab and pertuzumab. Previously, trastuzumab and pertuzumab were used separately or in combination to …

WebSelect patients for therapy based on an FDA-approved companion diagnostic test. PHESGO TM is indicated for use in combination with docetaxel for the treatment of adult patients … WebPHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer (MBC) who have not received prior …

WebNov 1, 2024 · Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection is a sterile, preservative-free, clear to opalescent, and colorless to slightly brownish solution … WebJun 29, 2024 · Today, the U.S. Food and Drug Administration approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the …

WebNov 30, 2024 · loss of consciousness. lower back, side, or stomach pain. mood or mental changes. muscle twitching. pinpoint red spots on the skin. severe sleepiness. stomach cramps. tremor. unusual drowsiness, dullness, or feeling of sluggishness.

WebJun 23, 2024 · Dosage. Phesgo dosage. For intravenous infusion only. Do not administer as an intravenous push or bolus. HER2 testing: Perform using FDA-approved tests by laboratories with demonstrated proficiency.. The initial Pertuzumab dose is 840 mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by … grant hill 3 on footWebAug 8, 2024 · Phesgo contains a combination of hyaluronidase, pertuzumab, and trastuzumabis. Phesgo is a cancer medicine that is used alone or with other medicines to … chip casopisWebPHESGO has different dosage and administration instructions than intravenous pertuzumab, intravenous trastuzumab, and subcutaneous trastuzumab when administered alone. Do not substitute PHESGO for or with pertuzumab, trastuzumab, ado-trastuzumab emtansine, or fam-trastuzumab deruxtecan. PHESGO must always be administered by a healthcare ... grant high school remodel videoWebPHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body … Most common side effects of PHESGO and tips you can try. The most common side … Taking PHESGO - PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) A … Patient Resources - PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) A … PHESGO may cause administration-related reactions: PHESGO is given as an … What is Phesgo - PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) A … Questions For Your Care Team - PHESGO® (pertuzumab / trastuzumab / … grant high school los angeles caWebNov 16, 2024 · PHESGO is compatible with stainless steel, polypropylene, polycarbonate, polyethylene, polyurethane, polyvinyl chloride and fluorinated ethylene polypropylene. Administration Administer PHESGO 1,200 mg, 600 mg, 30,000 units/15 mL subcutaneously over approximately 8 minutes chip catastral soachaWebJan 18, 2024 · Associate Professor. Department of Physics and Astronomy. SUNY College at Geneseo. 1 College Circle. Geneseo, NY 14454. Office: ISC 228D. Email pogo. Pogo & … grant hill and mosWebPHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use Initial U.S. Approval: 2024 . WARNING: CARDIOMYOPATHY, EMBRYO-FETAL TOXICITY, … grant hill alabama football cause of death